Android app on Google Play

UBS Maintains a 'Buy' on Par Pharmaceutical (PRX); Comments From Conference Call

May 9, 2012 12:21 PM EDT Send to a Friend
Get Alerts PRX Hot Sheet
Price: $49.98 --0%

Rating Summary:
    2 Buy, 8 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 24 | New: 21
Trade PRX Now!
Join SI Premium – FREE
UBS maintains a 'Buy' on Par Pharmaceutical (NYSE: PRX) price target raised from $42 to $48.

Analyst, Ami Fadia's Conference Call highlights: (1) Combined R&D efforts from legacy Par, Anchen and Edict teams have enabled Par to track ahead of its goal of 13-17 filings per year; (2) Mgt. expects ~10-14 new launches in the coming qtrs; (3) Base generic business saw minimum erosion in the quarter with a slight GM expansion; (4) 1Q R&D included $10M for the Dexilant deal and a $2M write down on a pipeline product; (5) While SG&A was light in 1Q, mgt. indicated that it is on track to meet full yr guidance of ~$180M; (6) Management remains confident in its Lovaza application/ court case and is ready for a launch."

UBS adjusts FY12 EPS estimate from $4.03 to $3.96.

For an analyst ratings summary and ratings history on Par Pharmaceutical click here. For more ratings news on Par Pharmaceutical click here.

Shares of Par Pharmaceutical closed at $42.08 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

UBS

Add Your Comment